DTx Pharma in the news

DTx’s pipeline includes programs developing treatments for rare diseases affecting the peripheral nervous system, skeletal muscle, CNS and other tissues. Read more about our pipeline: https://t.co/tXxHCaOwhK #RNAtherapeutics #raredisease https://t.co/3O0WpBGH3V

#ICYMI DTx’s CEO and founder Dr. Arthur Suckow joined James Mackay and Eslie Dennis of @KyowaKirin_US in a discussion about working with #raredisease #patientcommunities to develop new treatments. Listen to the @Biotech2050Pod episode: https://t.co/tVsnw5Fa8b https://t.co/c9Ji054bin

The CMT Research Foundation is doing important work highlighting this devastating #raredisease and working with scientists and patients to develop treatments. We’re proud to partner with @CMTRF and share in this mission as we develop a potential treatment for #CMT1A. https://t.co/HnyBsDtYCC